Occult primary.

Overview Occult primary tumors, or cancers of unknown primary (CUPs), are defined as histologically proven metastatic malignant tumors whose primary site cannot be identified during pretreatment evaluation.1,2 They have a wide variety of clinical presentations and a poor prognosis in most patients. Patients with occult primary tumors often present with general complaints, such as anorexia and weight loss. Clinical absence of primary tumor, early dissemination, aggressiveness, and unpredictability of metastatic pattern are characteristic of these tumors.3 Life expectancy is very short, with a median survival of 6 to 9 months.4 In most patients, occult primary tumors are refractory to systemic treatments, and chemotherapy NCCN

[1]  M. Erlander,et al.  Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial. , 2010 .

[2]  Denise,et al.  Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. , 2010, The oncologist.

[3]  W. E. Jordan,et al.  Cancer of unknown primary site. , 2010, Seminars in oncology.

[4]  R. Aharonov,et al.  Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin , 2010, Modern Pathology.

[5]  F. Monzon,et al.  Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. , 2010, Archives of pathology & laboratory medicine.

[6]  F. Monzon,et al.  Diagnosis of uncertain primary tumors with the Pathwork® tissue-of-origin test , 2010, Expert review of molecular diagnostics.

[7]  A. Gothelf,et al.  Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study , 2010, Acta oncologica.

[8]  J. Hainsworth,et al.  Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site: A Randomized, Phase III Sarah Cannon Oncology Research Consortium Trial , 2010, Cancer journal.

[9]  J. Hainsworth,et al.  Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. , 2009, The oncologist.

[10]  L. Truong,et al.  Undifferentiated tumor: true identity by immunohistochemistry. , 2009, Archives of pathology & laboratory medicine.

[11]  R. Salunga,et al.  Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. , 2009, Archives of pathology & laboratory medicine.

[12]  G. Calais,et al.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. , 2009, Journal of the National Cancer Institute.

[13]  R. Coleman,et al.  NCCN task force: clinical utility of PET in a variety of tumor types. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  F. Monzon,et al.  Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. French,et al.  Carcinomas of the Upper Aerodigestive Tract With Rearrangement of the Nuclear Protein of the Testis (NUT) Gene (NUT Midline Carcinomas) , 2009, Advances in anatomic pathology.

[16]  M. Erlander,et al.  Molecular classification of unknown primary cancer. , 2009, Seminars in oncology.

[17]  J. Hainsworth,et al.  Neuroendocrine carcinoma of unknown primary site. , 2009, Seminars in oncology.

[18]  S. Culine Prognostic factors in unknown primary cancer. , 2009, Seminars in oncology.

[19]  K. Oien,et al.  Pathologic evaluation of unknown primary cancer. , 2009, Seminars in oncology.

[20]  J. Hainsworth,et al.  Treatment for patients with unknown primary cancer and favorable prognostic factors. , 2009, Seminars in oncology.

[21]  G. Varadhachary,et al.  Overview of patient management and future directions in unknown primary carcinoma. , 2009, Seminars in oncology.

[22]  P. Schőffski,et al.  Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial , 2008, British Journal of Cancer.

[23]  Kenneth R Hess,et al.  Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Aharonov,et al.  MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.

[25]  M. Wick Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors. , 2008, Annals of diagnostic pathology.

[26]  T. Economopoulos,et al.  Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study , 2008, Acta oncologica.

[27]  M. Morrow,et al.  MRI and breast cancer: role in detection, diagnosis, and staging. , 2007, Oncology.

[28]  K. Griffith,et al.  Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site , 2007, Cancer.

[29]  N. Saijo,et al.  Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 , 2007, British Journal of Cancer.

[30]  B. Skogseid,et al.  Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors , 2007, Clinical Cancer Research.

[31]  J. Hainsworth,et al.  Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Mackey,et al.  The role of 2‐deoxy‐2‐[F‐18]fluoro‐D‐glucose positron emission tomography in disseminated carcinoma of unknown primary site , 2007, Cancer.

[33]  V. Ambrosini,et al.  18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin , 2006, La radiologia medica.

[34]  J. Hainsworth,et al.  Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  David C. Atkins,et al.  A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. , 2006, The Journal of molecular diagnostics : JMD.

[36]  K. Fizazi Carcinoma of an Unknown Primary Site , 2006 .

[37]  M. Mancini,et al.  Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[38]  Jeffrey W. Clark,et al.  Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Carles,et al.  Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  E. Morris,et al.  Utility of Breast Magnetic Resonance Imaging in Patients With Occult Primary Breast Cancer , 2005, Annals of Surgical Oncology.

[41]  N. Pavlidis,et al.  Cancer of unknown primary (CUP). , 2005, Critical reviews in oncology/hematology.

[42]  Mack Roach,et al.  Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond , 2005, CA: a cancer journal for clinicians.

[43]  C. Nanni,et al.  Role of 18F-FDG PET–CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  Howard,et al.  Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. , 2004, The oncologist.

[45]  C. Antonescu,et al.  Midline carcinoma of children and young adults with NUT rearrangement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Demir,et al.  The role of nuclear medicine in the diagnosis of cancer of unknown origin. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[47]  R. Lenzi,et al.  Diagnostic strategies for unknown primary cancer , 2004, Cancer.

[48]  J. Jassem,et al.  Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. , 2004, Cancer treatment reviews.

[49]  S. Culine,et al.  Gemcitabine and docetaxel as front‐line chemotherapy in patients with carcinoma of an unknown primary site , 2004, Cancer.

[50]  A. Hartmann,et al.  Cancer of unknown primary: clinicopathologic correlations , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[51]  P. Petrow,et al.  Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Hainsworth,et al.  Diagnostic and therapeutic management of cancer of an unknown primary. , 2003, European journal of cancer.

[53]  S. Culine,et al.  Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002) , 2003, British Journal of Cancer.

[54]  R. Delgado-Bolton,et al.  Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  N. Pavlidis Cancer of unknown primary: biological and clinical characteristics. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  H. Hillen,et al.  The unknown biology of the unknown primary tumour: a literature review. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  P. Chu,et al.  Keratin expression in human tissues and neoplasms , 2002, Histopathology.

[58]  J. Hainsworth,et al.  Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M Dietel,et al.  Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. , 2001, American journal of clinical pathology.

[60]  M. Fjällskog,et al.  Treatment with cisplatin and etoposide in patients with neuroendocrine tumors , 2001, Cancer.

[61]  J. Hainsworth,et al.  Taxane-based chemotherapy for patients with carcinoma of unknown primary site. , 2001, Cancer journal.

[62]  J. Hainsworth,et al.  Carcinoma of unknown primary site , 2000, Cancer.

[63]  H. Hillen Unknown primary tumours , 2000, Postgraduate medical journal.

[64]  N. Pavlidis,et al.  Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  P. Chu,et al.  Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases , 2000, Modern Pathology.

[66]  J. Olson,et al.  Magnetic Resonance Imaging Facilitates Breast Conservation for Occult Breast Cancer , 2000, Annals of Surgical Oncology.

[67]  J. Hainsworth,et al.  Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  K R Hess,et al.  Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  S. Edge,et al.  Breast MRI in the Evaluation of Patients with Occult Primary Breast Carcinoma , 1999, The breast journal.

[70]  N. Pavlidis,et al.  Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. , 1998, Anticancer research.

[71]  J. Roodenburg,et al.  Detection of unknown occult primary tumors using positron emission tomography , 1998, Cancer.

[72]  J. Hainsworth,et al.  Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  K. Hess,et al.  Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  K. Hess,et al.  Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  B. Jeremic,et al.  Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. , 1993, Journal of chemotherapy.

[76]  J. Hainsworth,et al.  Treatment of patients with cancer of an unknown primary site. , 1993, The New England journal of medicine.

[77]  F. Muggia,et al.  Management of peritoneal carcinomatosis of unknown primary tumor site. , 1993, Seminars in oncology.

[78]  J. Hainsworth,et al.  Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  J. Hainsworth,et al.  Tumors of unknown origin , 1992, CA: a cancer journal for clinicians.

[80]  L. Kvols,et al.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms , 1991, Cancer.

[81]  J. Hainsworth,et al.  Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. , 1989, Annals of internal medicine.

[82]  Y. Bécouarn,et al.  Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. , 1989, European journal of cancer & clinical oncology.

[83]  M. Wick,et al.  Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. , 1989, Human pathology.

[84]  J. Hainsworth,et al.  Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. , 1988, Annals of internal medicine.

[85]  M. Tattersall,et al.  Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. , 1987, European journal of cancer & clinical oncology.

[86]  T. Saclarides,et al.  Hormone receptor studies in axillary metastases from occult breast cancers , 1987, Cancer.

[87]  T. Keane,et al.  Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases , 1987, Cancer.

[88]  T. Therneau,et al.  Lack of Value for Cisplatin Added to Mitomycin‐Doxorubicin Combination Chemotherapy for Carcinoma of Unknown Primary Site A Randomized Trial , 1987, American journal of clinical oncology.

[89]  M. Burgess,et al.  Prognostic factors in metastatic carcinoma of unknown primary. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  R. Goldberg,et al.  5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  M. Tattersall,et al.  Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. , 1980, The New England journal of medicine.

[92]  Cx Utrecht Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis , 2009 .

[93]  J. Pollack,et al.  Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. , 2008, The Journal of molecular diagnostics : JMD.

[94]  J. Debatin,et al.  Unknown primary tumors: detection with dual-modality PET/CT--initial experience. , 2005, Radiology.

[95]  David W Townsend,et al.  PET/CT today and tomorrow. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[96]  A. Griffioen,et al.  Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. , 2004, Anticancer research.

[97]  V. Anand,et al.  Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. , 1995, Cancer investigation.

[98]  J. Verweij,et al.  Carcinoma of unknown primary: identification of a treatable subset? , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[99]  G. Falkson,et al.  Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. , 1989, Medical and pediatric oncology.

[100]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.